COVID-19: Leaked data suggests antiviral drug remdesivir is not effective treatment

Remdesivir, a closely-watched experimental COVID-19 treatment, has appeared to have failed its first clinical trial in China. A leaked draft summary of the trial indicated 237 patients were involved in the trial -- 158 were given remdesivir and 79 received a placebo. After a month, slightly more remdesivir patients died than those who had taken the placebo. The summary also said that the antiviral drug was not associated with any "clinical or virological benefits". However, Gilead Sciences -- the company behind the drug -- noted the trial was stopped early because it had too few patients, which means the results are not statistically meaningful.

Subscribe to our channel here: https://cna.asia/youtubesub

Subscribe to our news service on Telegram: https://cna.asia/telegram

Follow us:
CNA: https://cna.asia
CNA Lifestyle: http://www.cnalifestyle.com
Facebook: Facebook: channelnewsasia
Instagram: Instagram: channelnewsasia
Twitter: Twitter: channelnewsasia

• #news_politics
• #cna
• #channel_newsasia
• #covid_19
• #vaccine
• #clinical_trial
• #remdesivir
• #gilead
• #who
• #donald_trump
• #anti_malaria
• #antibiotics
• #experimental
• #hydroxychloroquine